Study-Related Findings from HER2 PET and Paired Tumor Biopsy in 10 Patients in HER2-Low Pilot Study
| HER2 PET/CT results | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUV for spleen | SUV for liver* | SUV for left myocardium | Study-specific biopsies | ||||||||||
| Patient | Lesion site(s) | SUVmax for tumor | Max | Mean | Max | Mean | Max | Mean | TBR | Site | ER/PR/Ki-67 | HER2 IHC biopsy | HER2/C17 gene amplification quote |
| 1 | Liver | 12.9 | 2.6 | 1.9 | 9.1 | 7.8 | 3.1 | 2.2 | 6.8 | Liver | 100/100/19 | 1+ | 2.85/1.0/2.85 |
| 2 | Bone, lymph nodes | 6.1 | 3.9 | 2.6 | 13.7 | 7.0 | 4.4 | 3.0 | 2.3 | Lymph node | 0/0/95 | 1+ | |
| 3 | Liver | 28.7 | 3.0 | 1.8 | NA | NA | 4.1 | 2.6 | 15.9 | Liver | 80/70/NA | 2+ | 3.3/2.3/1.4 |
| 4 | Bone, liver | 10.7 | 5.0 | 3.3 | NA | NA | 3.2 | 2.2 | 3.2 | Liver | 80/70/78 | 1+ | 4.4/2.5/1.76 |
| 5 | Bone, liver | 24.9 | 3.9 | 2.6 | 13.4 | 10.2 | 4.1 | 2.9 | 9.6 | Liver | 30/0/60 | 0 | |
| 6 | Bone, skin, liver | 3.7 | 2.8 | 2.2 | NA | NA | 3.1 | 2.1 | 1.7 | Skin | 0/0/39 | 0 | |
| 7 | Breast, brain | 10.3 | 2.3 | 1.7 | 13.8 | 11.0 | 3.8 | 2.9 | 6.1 | Breast | 60/0/40 | 2+ | 3.6/1.45/2.48 |
| 8 | Liver | 33.4 | 2.7 | 2.1 | 13.3 | 9.7 | 4.1 | 3.0 | 15.9 | Liver | 95/0/3 | 2+ | 1.3/1.8/0.7 |
| 9 | Bone, liver | 19.0 | 3.0 | 2.3 | NA | NA | 3.7 | 3.0 | 8.3 | Liver | 95/95/13 | 2+ | 2.25/1.55/1.45 |
| 10 | Liver, bone | 12.0 | 2.7 | 1.6 | NA | NA | 2.7 | 1.8 | 7.5 | Liver | 0/0/33 | 2+ | 2.65/1.35/1.96 |
↵* Only given when possible to identify area without scatter from metastases in liver.
Max = maximum; NA = not available.